DNA vaccine that targets hemagglutinin to MHC class II molecules rapidly induces antibody-mediated protection against influenza

Journal of Immunology

Volumn 191, Issue 6, 2013, Pages 3221-3231

  Grodeland, Gunnveig ^a,b   Mjaaland, Siri ^b,c   Roux, Kenneth H ^d   Fredriksen, Agnete Brunsvik ^a   Bogen, Bjarne ^a,b  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

^b KG Jebsen Centre for Research on Influenza Vaccines   (Norway)

^c NORWEGIAN INSTITUTE OF PUBLIC HEALTH   (Norway)

^d FLORIDA STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DNA VACCINE; INFLUENZA VIRUS HEMAGGLUTININ; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2;

ADAPTIVE IMMUNITY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN PRESENTING CELL; ARTICLE; CONTROLLED STUDY; CROSS REACTION; DNA IMMUNIZATION; DRUG TARGETING; FEMALE; INFLUENZA; MOUSE; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE; VACCINE PRODUCTION;

ANIMALS; ANTIBODIES, VIRAL; BLOTTING, WESTERN; ENZYME-LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; HEMAGGLUTININS; HISTOCOMPATIBILITY ANTIGENS CLASS II; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA VACCINES; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; ORTHOMYXOVIRIDAE INFECTIONS; PANDEMICS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SPAIN; TRANSFECTION; VACCINES, DNA;

EID: 84884252300     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1300504     Document Type: Article

References (63)

1. Gatherer, D. 2009. The 2009 H1N1 influenza outbreak in its historical context. J. Clin. Virol. 45: 174-178.
2. Bavagnoli, L., and G. Maga. 2011. The 2009 influenza pandemic: promising lessons for antiviral therapy for future outbreaks. Curr. Med. Chem. 18: 5466-5475.
3. Perdue, M. L., F. Arnold, S. Li, A. Donabedian, V. Cioce, T. Warf, and R. Huebner. 2011. The future of cell culture-based influenza vaccine production. Expert Rev. Vaccines 10: 1183-1194.
4. Keitel, W. A., and R. L. Atmar. 2009. Vaccines for pandemic influenza: summary of recent clinical trials. Curr. Top. Microbiol. Immunol. 333: 431-451.
5. Puig Barberà, J., and D. González Vidal. 2007. MF59-adjuvanted subunit influenza vaccine: an improved interpandemic influenza vaccine for vulnerable populations. Expert Rev. Vaccines 6: 659-665.
6. Song, J. M., Y. C. Kim, E. O, R. W. Compans, M. R. Prausnitz, and S. M. Kang. 2012. DNA vaccination in the skin using microneedles improves protection against influenza. Mol. Ther. 20: 1472-1480.
7. Wei, H., S. D. Lenz, D. H. Thompson, and R. M. Pogranichniy. 2012. DNAvaccine platform development against H1N1 subtype of swine influenza A viruses. Viral Immunol. 25: 297-305.
8. Xie, H., T. Liu, H. Chen, X. Huang, and Z. Ye. 2007. Evaluating the vaccine potential of an influenza Aviral hemagglutinin and matrix double insertion DNA plasmid. Vaccine 25: 7649-7655.
9. Zhou, F., G. Wang, P. Buchy, Z. Cai, H. Chen, Z. Chen, G. Cheng, X. F. Wan, V. Deubel, and P. Zhou. 2012. A triclade DNA vaccine designed on the basis of a comprehensive serologic study elicits neutralizing antibody responses against all clades and subclades of highly pathogenic avian influenza H5N1 viruses. J. Virol. 86: 6970-6978.
10. Lin, S. C., Y. F. Lin, P. Chong, and S. C. Wu. 2012. Broader neutralizing antibodies against H5N1 viruses using prime-boost immunization of hyperglycosylated hemagglutinin DNA and virus-like particles. PLoS ONE 7: e39075.
11. Kawamura, H., and J. A. Berzofsky. 1986. Enhancement of antigenic potency in vitro and immunogenicity in vivo by coupling the antigen to anti-immunoglobulin. J. Immunol. 136: 58-65.
12. Carayanniotis, G., and B. H. Barber. 1987. Adjuvant-free IgG responses induced with antigen coupled to antibodies against class II MHC. Nature 327: 59-61.
13. Snider, D. P., and D. M. Segal. 1987. Targeted antigen presentation using crosslinked antibody heteroaggregates. J. Immunol. 139: 1609-1616.
14. Casten, L. A., and S. K. Pierce. 1988. Receptor-mediated B cell antigen processing. Increased antigenicity of a globular protein covalently coupled to antibodies specific for B cell surface structures. J. Immunol. 140: 404-410.
15. Lees, A., S. C. Morris, G. Thyphronitis, J. M. Holmes, J. K. Inman, and F. D. Finkelman. 1990. Rapid stimulation of large specific antibody responses with conjugates of antigen and anti-IgD antibody. J. Immunol. 145: 3594-3600.
16. Mjaaland, S., and S. Fossum. 1990. Modulation of immune responses with monoclonal antibodies. I. Effects on regional lymph node morphology and on anti-hapten responses to haptenized monoclonal antibodies. Eur. J. Immunol. 20: 1457-1461.
17. Skea, D. L., A. R. Douglas, J. J. Skehel, and B. H. Barber. 1993. The immunotargeting approach to adjuvant-independent immunization with influenza haemagglutinin. Vaccine 11: 994-1002.
18. Baier, G., G. Baier-Bitterlich, D. J. Looney, and A. Altman. 1995. Immunogenic targeting of recombinant peptide vaccines to human antigen-presenting cells by chimeric anti-HLA-DR and anti-surface immunoglobulin D antibody Fab fragments in vitro. J. Virol. 69: 2357-2365.
19. Estrada, A., M. R. McDermott, B. J. Underdown, and D. P. Snider. 1995. Intestinal immunization of mice with antigen conjugated to anti-MHC class II antibodies. Vaccine 13: 901-907.
20. Biragyn, A., K. Tani, M. C. Grimm, S. Weeks, and L. W. Kwak. 1999. Genetic fusion of chemokines to a self tumor antigen induces protective, T-cell dependent antitumor immunity. Nat. Biotechnol. 17: 253-258.
21. Lunde, E., L. A. Munthe, A. Vabø, I. Sandlie, and B. Bogen. 1999. Antibodies engineered with IgD specificity efficiently deliver integrated T-cell epitopes for antigen presentation by B cells. Nat. Biotechnol. 17: 670-675.
22. Caminschi, I., A. I. Proietto, F. Ahmet, S. Kitsoulis, J. Shin Teh, J. C. Lo, A. Rizzitelli, L. Wu, D. Vremec, S. L. van Dommelen, et al. 2008. The dendritic cell subtype-restricted C-type lectin Clec9A is a target for vaccine enhancement. Blood 112: 3264-3273.
23. Charalambous, A., M. Oks, G. Nchinda, S. Yamazaki, and R. M. Steinman. 2006. Dendritic cell targeting of survivin protein in a xenogeneic form elicits strong CD4+ T cell immunity to mouse survivin. J. Immunol. 177: 8410-8421.
24. Flamar, A. L., S. Zurawski, F. Scholz, I. Gayet, L. Ni, X. H. Li, E. Klechevsky, J. Quinn, S. Oh, D. H. Kaplan, et al. 2012. Noncovalent assembly of antidendritic cell antibodies and antigens for evoking immune responses in vitro and in vivo. J. Immunol. 189: 2645-2655.
25. Fredriksen, A. B., I. Sandlie, and B. Bogen. 2006. DNA vaccines increase immunogenicity of idiotypic tumor antigen by targeting novel fusion proteins to antigen-presenting cells. Mol. Ther. 13: 776-785.
26. Fredriksen, A. B., and B. Bogen. 2007. Chemokine-idiotype fusion DNAvaccines are potentiated by bivalency and xenogeneic sequences. Blood 110: 1797-1805.
27. Schjetne, K. W., A. B. Fredriksen, and B. Bogen. 2007. Delivery of antigen to CD40 induces protective immune responses against tumors. J. Immunol. 178: 4169-4176.
28. Hobson, D., R. L. Curry, A. S. Beare, and A. Ward-Gardner. 1972. The role of serum haemagglutination-inhibiting antibody in protection against challenge infection with influenza A2 and B viruses. J. Hyg. (Lond.) 70: 767-777.
29. Staudt, L. M., andW. Gerhard. 1983. Generation of antibody diversity in the immune response of BALB/c mice to influenza virus hemagglutinin. I. Significant variation in repertoire expression between individual mice. J. Exp. Med. 157: 687-704.
30. Roux, K. H. 1989. Immunoelectron microscopy of idiotype-anti-idiotype complexes. Methods Enzymol. 178: 130-144.
31. Roux, K. H. 1996. Negative-Stain Immunoelectron-Microscopic Analysis of Small Macromolecules of Immunologic Significance. Methods 10: 247-256.
32. Shastri, N., B. Malissen, and L. Hood. 1985. Ia-transfected L-cell fibroblasts present a lysozyme peptide but not the native protein to lysozyme-specific T cells. Proc. Natl. Acad. Sci. USA 82: 5885-5889.
33. Reed, L. J., and H. Muench. 1938. Simple method of estimating fifty percent endpoints. Am. J. Hyg. 27: 493-497.
34. Roos, A. K., S. Moreno, C. Leder, M. Pavlenko, A. King, and P. Pisa. 2006. Enhancement of cellular immune response to a prostate cancer DNA vaccine by intradermal electroporation. Mol. Ther. 13: 320-327.
35. Roos, A. K., F. Eriksson, D. C. Walters, P. Pisa, and A. D. King. 2009. Optimization of skin electroporation in mice to increase tolerability of DNA vaccine delivery to patients. Mol. Ther. 17: 1637-1642.
36. Prat, M., G. Gribaudo, P. M. Comoglio, G. Cavallo, and S. Landolfo. 1984. Monoclonal antibodies against murine gamma interferon. Proc. Natl. Acad. Sci. USA 81: 4515-4519.
37. Yang, Z., Y. J. Day, M. C. Toufektsian, Y. Xu, S. I. Ramos, M. A. Marshall, B. A. French, and J. Linden. 2006. Myocardial infarct-sparing effect of adenosine A2A receptor activation is due to its action on CD4+ T lymphocytes. Circulation 114: 2056-2064.
38. Andreasson, K., M. Eriksson, K. Tegerstedt, T. Ramqvist, and T. Dalianis. 2010. CD4+ and CD8+ T cells can act separately in tumour rejection after immunization with murine pneumotropic virus chimeric Her2/neu virus-like particles. PLoS ONE 5: e11580.
39. Norderhaug, L., T. Olafsen, T. E. Michaelsen, and I. Sandlie. 1997. Versatile vectors for transient and stable expression of recombinant antibody molecules in mammalian cells. J. Immunol. Methods 204: 77-87.
40. Altomonte, M., C. Pucillo, G. Damante, and M. Maio. 1993. Cross-linking of HLA class II antigens modulates the release of tumor necrosis factor-alpha by the EBV-B lymphoblastoid cell line JY. J. Immunol. 151: 5115-5122.
41. Andreae, S., S. Buisson, and F. Triebel. 2003. MHC class II signal transduction in human dendritic cells induced by a natural ligand, the LAG-3 protein (CD223). Blood 102: 2130-2137.
42. Baleeiro, R. B., K. H. Wiesmüller, L. Dähne, J. Lademann, J. A. Barbuto, and P. Walden. 2013. Direct activation of human dendritic cells by particle-bound but not soluble MHC class II ligand. PLoS ONE 8: e63039.
43. Lokshin, A. E., P. Kalinski, R. R. Sassi, R. B. Mailliard, J. Müller-Berghaus, W. J. Storkus, X. Peng, A. M. Marrangoni, R. P. Edwards, and E. Gorelik. 2002. Differential regulation of maturation and apoptosis of human monocyte-derived dendritic cells mediated by MHC class II. Int. Immunol. 14: 1027-1037.
44. Aihara, H., and J. Miyazaki. 1998. Gene transfer into muscle by electroporation in vivo. Nat. Biotechnol. 16: 867-870.
45. Peng, B., Y. Zhao, L. Xu, and Y. Xu. 2007. Electric pulses applied prior to intramuscular DNA vaccination greatly improve the vaccine immunogenicity. Vaccine 25: 2064-2073.
46. Roos, A. K., F. Eriksson, J. A. Timmons, J. Gerhardt, U. Nyman, L. Gudmundsdotter, A. Bråve, B. Wahren, and P. Pisa. 2009. Skin electroporation: effects on transgene expression, DNA persistence and local tissue environment. PLoS ONE 4: e7226.
47. Scott, B., R. Liblau, S. Degermann, L. A. Marconi, L. Ogata, A. J. Caton, H. O. McDevitt, and D. Lo. 1994. A role for non-MHC genetic polymorphism in susceptibility to spontaneous autoimmunity. Immunity 1: 73-83.
48. Tamura, M., K. Kuwano, I. Kurane, and F. A. Ennis. 1998. Definition of amino acid residues on the epitope responsible for recognition by influenza A virus H1-specific, H2-specific, and H1-and H2-cross-reactive murine cytotoxic Tlymphocyte clones. J. Virol. 72: 9404-9406.
49. Guo, H., F. Santiago, K. Lambert, T. Takimoto, and D. J. Topham. 2011. T cellmediated protection against lethal 2009 pandemic H1N1 influenza virus infection in a mouse model. J. Virol. 85: 448-455.
50. Hackett, C. J., B. Dietzschold,W. Gerhard, B. Ghrist, R. Knorr, D. Gillessen, and F. Melchers. 1983. Influenza virus site recognized by a murine helper T cell specific for H1 strains. Localization to a nine amino acid sequence in the hemagglutinin molecule. J. Exp. Med. 158: 294-302.
51. Batista, F. D., D. Iber, and M. S. Neuberger. 2001. B cells acquire antigen from target cells after synapse formation. Nature 411: 489-494.
52. Berg, S. F., S. Mjaaland, and S. Fossum. 1994. Comparing macrophages and dendritic leukocytes as antigen-presenting cells for humoral responses in vivo by antigen targeting. Eur. J. Immunol. 24: 1262-1268.
53. Boulay, F., R. W. Doms, R. G. Webster, and A. Helenius. 1988. Posttranslational oligomerization and cooperative acid activation of mixed influenza hemagglutinin trimers. J. Cell Biol. 106: 629-639.
54. Copeland, C. S., R. W. Doms, E. M. Bolzau, R. G. Webster, and A. Helenius. 1986. Assembly of influenza hemagglutinin trimers and its role in intracellular transport. J. Cell Biol. 103: 1179-1191.
55. Stevens, J., O. Blixt, L. Glaser, J. K. Taubenberger, P. Palese, J. C. Paulson, and I. A. Wilson. 2006. Glycan microarray analysis of the hemagglutinins from modern and pandemic influenza viruses reveals different receptor specificities. J. Mol. Biol. 355: 1143-1155.
56. Tan, L., H. Lu, D. Zhang, M. Tian, B. Hu, Z. Wang, and N. Jin. 2010. Protection against H1N1 influenza challenge by a DNA vaccine expressing H3/ H1 subtype hemagglutinin combined with MHC class II-restricted epitopes. Virol. J. 7: 363.
57. Tan, L., H. Lu, D. Zhang, K. Wang, M. Tian, C. Liu, Y. Liu, B. Hu, and N. Jin. 2011. Efficacy of seasonal pandemic influenza hemagglutinin DNA vaccines delivered by electroporation against a seasonal H1N1 virus challenge in mice. Sci China Life Sci 54: 293-299.
58. Xu, K., Z. Y. Ling, L. Sun, Y. Xu, C. Bian, Y. He, W. Lu, Z. Chen, and B. Sun. 2011. Broad humoral and cellular immunity elicited by a bivalent DNA vaccine encoding HA and NP genes from an H5N1 virus. Viral Immunol. 24: 45-56.
59. Einer-Jensen, K., L. Delgado, E. Lorenzen, G. Bovo, O. Evensen, S. Lapatra, and N. Lorenzen. 2009. Dual DNA vaccination of rainbow trout (Oncorhynchus mykiss) against two different rhabdoviruses, VHSV and IHNV, induces specific divalent protection. Vaccine 27: 1248-1253.
60. Kutzler, M. A., and D. B. Weiner. 2008. DNA vaccines: ready for prime time? Nat. Rev. Genet. 9: 776-788.
61. Fioretti, D., S. Iurescia, V. M. Fazio, and M. Rinaldi. 2010. DNA vaccines: developing new strategies against cancer. J. Biomed. Biotechnol. 2010: 174378.
62. Vasan, S., S. J. Schlesinger, Y. Huang, A. Hurley, A. Lombardo, Z. Chen, S. Than, P. Adesanya, C. Bunce, M. Boaz, et al. 2010. Phase 1 safety and immunogenicity evaluation of ADVAX, a multigenic, DNA-based clade C/B' HIV-1 candidate vaccine. PLoS ONE 5: e8617.
63. Martin, J. E., T. C. Pierson, S. Hubka, S. Rucker, I. J. Gordon, M. E. Enama, C. A. Andrews, Q. Xu, B. S. Davis, M. Nason, et al. 2007. A West Nile virus DNA vaccine induces neutralizing antibody in healthy adults during a phase 1 clinical trial. J. Infect. Dis. 196: 1732-1740.